<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006000</article-id><article-id pub-id-type="pmc">PMC11859719</article-id><article-id pub-id-type="doi">10.3390/ph18020186</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00186</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>GABA<sub>A</sub> Receptors Are Involved in the Seizure Blockage Prompted by a Polyphenol-Rich Extract of White Grape Juice in Rodents</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8670-3123</contrib-id><name><surname>Maugeri</surname><given-names>Alessandro</given-names></name><xref rid="af1-pharmaceuticals-18-00186" ref-type="aff">1</xref><xref rid="fn1-pharmaceuticals-18-00186" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6746-6751</contrib-id><name><surname>Citraro</surname><given-names>Rita</given-names></name><xref rid="af2-pharmaceuticals-18-00186" ref-type="aff">2</xref><xref rid="fn1-pharmaceuticals-18-00186" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0061-1608</contrib-id><name><surname>Leo</surname><given-names>Antonio</given-names></name><xref rid="af2-pharmaceuticals-18-00186" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7770-0457</contrib-id><name><surname>Russo</surname><given-names>Caterina</given-names></name><xref rid="af3-pharmaceuticals-18-00186" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6492-7820</contrib-id><name><surname>Navarra</surname><given-names>Michele</given-names></name><xref rid="af3-pharmaceuticals-18-00186" ref-type="aff">3</xref><xref rid="c1-pharmaceuticals-18-00186" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7629-6579</contrib-id><name><surname>De Sarro</surname><given-names>Giovambattista</given-names></name><xref rid="af2-pharmaceuticals-18-00186" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Chen</surname><given-names>Chung-Yi</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00186"><label>1</label>Department of Veterinary Sciences, University of Messina, I-98168 Messina, Italy; <email>amaugeri@unime.it</email></aff><aff id="af2-pharmaceuticals-18-00186"><label>2</label>Department of Science of Health, School of Medicine and Surgery, University &#x0201c;Magna Gr&#x000e6;cia&#x0201d; of Catanzaro, I-88100 Catanzaro, Italy; <email>citraro@unicz.it</email> (R.C.); <email>aleo@unicz.it</email> (A.L.); <email>desarro@unicz.it</email> (G.D.S.)</aff><aff id="af3-pharmaceuticals-18-00186"><label>3</label>Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, I-98168 Messina, Italy; <email>caterina.russo1@unime.it</email></aff><author-notes><corresp id="c1-pharmaceuticals-18-00186"><label>*</label>Correspondence: <email>mnavarra@unime.it</email></corresp><fn id="fn1-pharmaceuticals-18-00186"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>186</elocation-id><history><date date-type="received"><day>13</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>28</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> Polyphenols have been suggested to possess anticonvulsant properties, which can be exploited as tools in novel strategies against epilepsy. Along that line, the aim of this study was to investigate the effects of a polyphenol-rich extract of white grape juice (WGJe) in different rodent models of epilepsy, exploring its putative mechanism of action. <bold>Methods</bold>: In this study, we employed pentylenetetrazole (PTZ)-injected ICR-CD1 mice, audiogenic seizure (AGS)-susceptible DBA/2 mice and WAG/Rij rats. Seizures were monitored and scored, while absence was assessed by electroencephalogram. The open-field test was employed to assess the anxiolytic effects of WGJe. In order to assess the involvement of the GABA<sub>A</sub> receptor, we used the antagonist flumazenil in AGS-susceptible DBA/2 mice. Computational analyses were employed to evaluate the interaction of the main polyphenols of WGJe and GABA<sub>A</sub> receptors. <bold>Results</bold>: Our results showed that the intraperitoneal injection of WGJe hindered tonic seizures in PTZ-injected ICR-CD1 mice. In WAG/Rij rats, WGJe did not elicit any significant effects on spike-wave discharges compared to untreated rats. In AGS-susceptible DBA/2 mice, WGJe significantly hampered both clonic and tonic seizures, as well as induced anxiolytic effects. Interestingly, when administering WGJe with flumazenil to DBA/2 mice, we noted that the observed effects were mediated by the GABA<sub>A</sub> receptor. Moreover, docking simulations confirmed that the main polyphenols of WGJe are able to interact with the benzodiazepine sites located in both extracellular and transmembrane domains in the GABA<sub>A</sub> receptor. <bold>Conclusions:</bold> This study outlines the mechanism underlying the anti-epileptic activity of WGJe, thus supporting its potential role in the management of epilepsy.</p></abstract><kwd-group><kwd>grape juice</kwd><kwd><italic toggle="yes">Vitis vinifera</italic></kwd><kwd>polyphenols</kwd><kwd>seizures</kwd><kwd>epilepsy</kwd><kwd>natural products</kwd><kwd>molecular docking</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00186"><title>1. Introduction</title><p>According to the last definition proposed by the International League Against Epilepsy (ILAE), epileptic syndrome is a characteristic cluster of clinical and electroencephalogram features, which is often supported by specific etiological findings (i.e., structural, genetic, metabolic, immune and infectious). Moreover, diagnosis frequently carries prognostic and treatment implications, since epileptic syndromes often have age-dependent manifestations and a range of specific comorbidities [<xref rid="B1-pharmaceuticals-18-00186" ref-type="bibr">1</xref>]. Epilepsy affects as many as 70 million individuals globally and has an incidence of 50/100,000 patients per year and a prevalence of 700/100,000, accounting for more than 0.5% of the total worldwide illness burden [<xref rid="B2-pharmaceuticals-18-00186" ref-type="bibr">2</xref>]. The main strategy for treating the majority of cases is the employment of drugs, both in monotherapy as well as in combination, for drug-resistant conditions [<xref rid="B3-pharmaceuticals-18-00186" ref-type="bibr">3</xref>]. Antiseizure drugs (ASDs) were introduced into clinical practice several decades ago and their development is unceasing. Indeed, the first generation of ASDs started with phenobarbital, which was followed by many other different molecules. In the late 1980s, the second generation started with vigabatrin and continued until the early 2000 with the approval of pregabalin, which set off the third generation of ASDs [<xref rid="B3-pharmaceuticals-18-00186" ref-type="bibr">3</xref>]. Currently, the last approved ASDs by FDA in the USA and EMA in Europe are cenobamate for focal seizures in adults and fenfluramine for seizures in Dravet syndrome (DS) [<xref rid="B4-pharmaceuticals-18-00186" ref-type="bibr">4</xref>]. In addition to synthetic ASDs, natural products have been claimed to possess anti-epileptic potential. The most relevant case is that of cannabidiol, which was approved for treatment in 2018 [<xref rid="B5-pharmaceuticals-18-00186" ref-type="bibr">5</xref>]. It is characterized by a complex mechanism of action, including modulation of neurotransmitters (i.e., glutamate and &#x003b3;-aminobutyric acid&#x02014;GABA), intracellular proteins (i.e., phosphatidylinositol 3-kinase) and the endocannabinoid system [<xref rid="B6-pharmaceuticals-18-00186" ref-type="bibr">6</xref>]. The multi-target capability of cannabidiol also applies to other natural products, forming the characteristic of these products and the element exploitable in therapy, especially in resistant forms of epilepsy [<xref rid="B7-pharmaceuticals-18-00186" ref-type="bibr">7</xref>]. From a pre-clinical point of view, many studies have been conducted on polyphenols in relation to diseases affecting the central nervous system, among which is epilepsy [<xref rid="B8-pharmaceuticals-18-00186" ref-type="bibr">8</xref>].</p><p>The health-promoting properties of white grape (<italic toggle="yes">Vitis vinifera</italic> L.) are widely acknowledged, which are due to the presence of different active compounds, mainly polyphenols [<xref rid="B9-pharmaceuticals-18-00186" ref-type="bibr">9</xref>]. Along this line, we previously demonstrated that a polyphenol-rich extract of white grape juice (WGJe) was able, in vitro, to reduce both drug-induced toxicity [<xref rid="B10-pharmaceuticals-18-00186" ref-type="bibr">10</xref>] and microbial proliferation [<xref rid="B11-pharmaceuticals-18-00186" ref-type="bibr">11</xref>], whereas, in vivo, it elicited neuroprotective effects in a mouse model of multiple sclerosis [<xref rid="B12-pharmaceuticals-18-00186" ref-type="bibr">12</xref>] and reduced fat accumulation in obese zebrafish [<xref rid="B13-pharmaceuticals-18-00186" ref-type="bibr">13</xref>].</p><p>Based on these premises, we assessed the potential anticonvulsant effects of WGJe in different rodent models of epilepsy, investigating the putative mechanism of action.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00186"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-18-00186"><title>2.1. Polyphenolic Profile of WGJe</title><p>As previously described [<xref rid="B10-pharmaceuticals-18-00186" ref-type="bibr">10</xref>,<xref rid="B12-pharmaceuticals-18-00186" ref-type="bibr">12</xref>], the quali-quantitative composition of WGJe determined by UPLC/QqQ&#x02013;MS/MS analysis contained several polyphenolic classes, among which flavonols, flavanols, hydroxycinnamates and resveratrols (<xref rid="pharmaceuticals-18-00186-t001" ref-type="table">Table 1</xref>). In detail, the most abundant compounds (more than 2 g/kg of WGJe) were quercetin-3-glucuronide, quercetin-3-glucoside, procyanidin B1 and B3, catechin, trans-coutaric acid and cis-piceid.</p></sec><sec id="sec2dot2-pharmaceuticals-18-00186"><title>2.2. Effects of WGJe Treatment on Pentylenetetrazole (PTZ)-Induced Seizures</title><p>Mice pre-treated with the vehicle, before pentylenetetrazole (PTZ) injection, an inhibitor of the GABA<sub>A</sub> receptor, showed both clonic and tonic seizures, and 80% died within 30 min. WGJe (20 mg/kg intraperitoneally&#x02014;i.p.), administered 30, 60 and 120 min before PTZ injection, did not significantly (<italic toggle="yes">p</italic> &#x0003e; 0.05) change the incidence of either tonic or clonic seizures. At odds, the treatment with WGJe from 40 mg/kg to 120 mg/kg, 30 min before PTZ injection, produced significant (<italic toggle="yes">p</italic> &#x0003c; 0.01) dose-dependent protection against tonic seizures (<xref rid="pharmaceuticals-18-00186-f001" ref-type="fig">Figure 1</xref>) with a ED<sub>50</sub> value of 57.76 (45.48&#x02013;73.36) mg/kg (<xref rid="pharmaceuticals-18-00186-t002" ref-type="table">Table 2</xref>). However, WGJe did not significantly (<italic toggle="yes">p</italic> &#x0003e; 0.05) influence the incidence of clonic seizures. Similarly, WGJe at the doses of 40, 80, 100 and 120 mg/kg, administered 60 and 120 min before PTZ, was not effective against clonic and tonic seizures.</p></sec><sec id="sec2dot3-pharmaceuticals-18-00186"><title>2.3. Effects of WGJe on Absence Seizures in WAG/Rij Rats</title><p>All WAG/Rij rats, at 6 months of age, exhibited spontaneously occurring spike-wave discharges (SWDs) on electroencephalograms (EEGs). The mean number of SWDs (nSWDs) for a 30 min epoch was 6.78 &#x000b1; 1.18 seizures, with a mean total duration (dSWDs) of 21.5 &#x000b1; 4.24 s and a mean single duration (sSWD) of 3.17 &#x000b1; 0.8 s. The i.p. administration of WGJe in WAG/Rij rats, at the doses reported above, did not significantly (<italic toggle="yes">p</italic> &#x0003e; 0.05) modify the nSWDs and/or dSWDs in comparison to untreated rats.</p></sec><sec id="sec2dot4-pharmaceuticals-18-00186"><title>2.4. Effects of WGJe on Audiogenic Seizure (AGS)-Prone DBA/2 Mice</title><p>WGJe injection at the dose of 20 mg/kg, 30, 60 and 120 min before auditory stimulation, did not significantly (<italic toggle="yes">p</italic> &#x0003e; 0.05) affect the occurrence of either clonic or tonic seizures in audiogenic seizure (AGS)-prone DBA/2 mice. Conversely, the administration of WGJe from 40 to 120 mg/kg i.p., 30 min before auditory stimulation, significantly (<italic toggle="yes">p</italic> &#x0003c; 0.01) protected, in a dose-dependent manner, against the clonic and tonic phases of the audiogenic seizure (<xref rid="pharmaceuticals-18-00186-f002" ref-type="fig">Figure 2</xref>A,B), with ED<sub>50</sub> values of 60.68 (45.76&#x02013;80.47) and 47.83 (33.17&#x02013;68.96) mg/kg for clonus and tonus, respectively. Furthermore, WGJe (40&#x02013;120 mg/kg) was also effective against the wild running phase of reflex seizures in DBA/2 mice, with an ED<sub>50</sub> of 89.28 (62.31&#x02013;127.91) mg/kg (<xref rid="pharmaceuticals-18-00186-t002" ref-type="table">Table 2</xref>). On the contrary, the administration of WGJe, from 40 mg/kg to 120 mg/kg, 60 and 120 min before auditory stimulation, did not significantly (<italic toggle="yes">p</italic> &#x0003e; 0.05) change the incidence of tonic and clonic seizures.</p><p>Interestingly, the administration of flumazenil (2.5 mg/kg, i.p.), a GABA<sub>A</sub> receptor antagonist, was performed to investigate the potential contribution of this receptor to the antiseizure effects of WGJe. Flumazenil, in combination with WGJe, moved dose&#x02013;response curves to the right (<xref rid="pharmaceuticals-18-00186-f002" ref-type="fig">Figure 2</xref>A,B) and significantly (<italic toggle="yes">p</italic> &#x0003c; 0.01) augmented the ED<sub>50</sub> values up to 98.95 (73.65&#x02013;132.93) mg/kg for clonus and 73.94 (55.05&#x02013;99.30) mg/kg for tonus (<xref rid="pharmaceuticals-18-00186-t002" ref-type="table">Table 2</xref>). Likewise, WGJe co-administered with flumazenil did not protect mice against wild running in comparison to WGJe administered alone (<xref rid="pharmaceuticals-18-00186-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec2dot5-pharmaceuticals-18-00186"><title>2.5. Open-Field Test (OFT) in Treated and Untreated DBA/2 Mice</title><p>The distance moved and mean velocity did not significantly differ between treated and untreated DBA/2 mice in the OFT, supporting the absence of a locomotor deficit. The time spent in the center along with the number of entries, which are inversely linked to the level of anxiety in mice [<xref rid="B14-pharmaceuticals-18-00186" ref-type="bibr">14</xref>], were significantly (<italic toggle="yes">p</italic> &#x0003c; 0.01) increased in WGJe-treated DBA/2 mice, at the doses of 40, 80, 100 and 120 mg/kg, in comparison to untreated DBA/2 mice (<xref rid="pharmaceuticals-18-00186-f003" ref-type="fig">Figure 3</xref>A,B). The i.p. administration of flumazenil (2.5 mg/kg), 15 min before the test, was able to antagonize the anxiolytic-like effect of WGJe, at 40, 80 and 100 mg/kg, in DBA/2 mice. Conversely, the anxiolytic-like effect of WGJe at 120 mg/kg was not antagonized by flumazenil (<xref rid="pharmaceuticals-18-00186-f003" ref-type="fig">Figure 3</xref>A,B).</p></sec><sec id="sec2dot6-pharmaceuticals-18-00186"><title>2.6. Molecular Docking of the Main Components of WGJe in the GABA<sub>A</sub> Receptor</title><p>Based on the antagonistic effects observed by the employment of flumazenil, we investigated the potential interaction between the most representative polyphenols present in WGJe and the GABA<sub>A</sub> receptor. We chose the compounds present at a concentration of &#x0003c;2 g/kg in WGJe, excluding procyanidin B1 and B3 given their high molecular weight, while preferring their monomers. Ultimately, we assessed the binding capacity of catechin, cis-piceid, trans-coutaric acid, epicatechin, quercetin, quercetin-3-glucoronide and quercetin-3-glucoside.</p><p>The crystal structure of the GABA<sub>A</sub> receptor bound to the positive allosteric modulator diazepam was employed (PDB: 6X3X). In detail, diazepam can bind at the classical benzodiazepine site in the extracellular domain (ECD) of the &#x003b1;-&#x003b3; interface as well as in the transmembrane domain (TMD) at the &#x003b2;-&#x003b1; interface [<xref rid="B15-pharmaceuticals-18-00186" ref-type="bibr">15</xref>]. Therefore, these two binding domains were chosen for docking simulations of the most representative polyphenols present in WGJe (<xref rid="pharmaceuticals-18-00186-f004" ref-type="fig">Figure 4</xref>).</p><p>As shown in <xref rid="pharmaceuticals-18-00186-t003" ref-type="table">Table 3</xref>, all the selected polyphenols displayed the capability to interact at both binding sites of benzodiazepines. In particular, at the ECD site, according to the ChemPLP algorithm, the compounds that scored the best were quercetin-3-glucoside (110.93) and quercetin-3-glucoronide (109.34), followed by cis-piceid (80.50), which showed also the lowest root mean square deviation (RMSD) of atomic positions, meaning it is close to the co-crystallized ligand. Interestingly, the ChemPLP scores of reference ligands diazepam and flumazenil were 77.02 and 83.96, respectively, suggesting that the best-scoring WGJe polyphenols are able to theoretically create more interactions with the GABA<sub>A</sub> receptor. These results were also confirmed by the GoldScore algorithm. At the TMD site as well, the polyphenols quercetin-3-glucoside (76.39), cis-piceid (72.11) and quercetin-3-glucoronide (68.06) represented the best docked compounds, and yet the latter showed the lowest RMSD value. These values were comparable to the fitness score of diazepam docked at the same site (73.09). According to GoldScore, quercetin-3-glucoronide and quercetin-3-glucoside possessed similar fitness scores (72.72 and 72.02, respectively), followed by cis-piceid (61.13).</p><p>As shown in <xref rid="pharmaceuticals-18-00186-f005" ref-type="fig">Figure 5</xref>A, the selected polyphenols followed a pattern of binding similar to that of the crystallized ligand (diazepam) at the ECD site. Regarding the highest-ranking polyphenols, cis-piceid was able to form &#x003c0;-&#x003c0; stacking with Phe100 of the &#x003b1;<sub>1</sub> subunit, like diazepam, as well as with Tyr58 of the &#x003b3;<sub>2</sub> subunit. The H-bonds formed with Asn60 and Asp162 of the &#x003b1;<sub>1</sub> subunit, along with Ser159 of the &#x003b3;<sub>2</sub> subunit (<xref rid="pharmaceuticals-18-00186-f005" ref-type="fig">Figure 5</xref>B). Quercetin-3-glucoronide maintains the H-bond with Ser206, while strongly interacting with Gln240 and Glu198 of the &#x003b1;<sub>1</sub> and &#x003b3;<sub>2</sub> subunits, respectively. Moreover, the benzo-&#x003b3;-pyrone moiety forms &#x003c0;-&#x003c0; stacking with Tyr160 and a hydrogen bond with Ala169 of the &#x003b1;<sub>1</sub> subunit (<xref rid="pharmaceuticals-18-00186-f005" ref-type="fig">Figure 5</xref>C). Interestingly, the same pattern of interactions is present for quercetin-3-glucoside, though the H-bond with Ser206 is lost due to the lack of the carboxyl group in the glucose moiety (<xref rid="pharmaceuticals-18-00186-f005" ref-type="fig">Figure 5</xref>D).</p><p>Similarly to what was observed at the ECD site, WGJe polyphenols stacked at the TMD site following the binding mode of diazepam, though with differences in projection towards the core of the receptor (<xref rid="pharmaceuticals-18-00186-f006" ref-type="fig">Figure 6</xref>A). Both quercetin-3-glucoronide (<xref rid="pharmaceuticals-18-00186-f006" ref-type="fig">Figure 6</xref>C) and quercetin-3-glucoside (<xref rid="pharmaceuticals-18-00186-f006" ref-type="fig">Figure 6</xref>D) form an H-bond with Asn265 of the &#x003b2;<sub>2</sub> subunit, while the latter interacts with Ile228, like cis-piceid (<xref rid="pharmaceuticals-18-00186-f006" ref-type="fig">Figure 6</xref>B). Interestingly, quercetin-3-glucoside also forms tight &#x003c0;-&#x003c0; stacking with Phe289 and an H-bond with Pro233, while cis-piceid interacts with Ser272.</p></sec></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-18-00186"><title>3. Discussion</title><p>The scientific community has established the role of natural products in counteracting the onset of seizures. Indeed, centuries of traditional medicine have proven the capability of polyphenols, alkaloids and terpenoids to help manage epilepsy [<xref rid="B16-pharmaceuticals-18-00186" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-18-00186" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-18-00186" ref-type="bibr">18</xref>]. Moreover, the general population is rising quickly, particularly in developing nations, so finding affordable and easily available medications is an important goal to achieve. Additionally, since they may have various modes of action, plant-derived drugs might be of invaluable benefit in epilepsy by overcoming resistance [<xref rid="B19-pharmaceuticals-18-00186" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-18-00186" ref-type="bibr">20</xref>].</p><p>Along this line, we are the first to report that WGJe possesses anti-epileptic effects, as assessed in different rodent models. In detail, we observed that WGJe was able to counteract only tonic seizures in PTZ-injected ICR-CD1 mice in a dose-dependent manner. The inefficacy of WGJe to hamper clonic seizures in PTZ-injected mice suggests that this extract may act like benzodiazepines. Gasior and co-workers demonstrated that diazepam displayed anti-epileptogenic effects against tonic seizures, and yet not on clonic ones in PTZ-injected mice [<xref rid="B21-pharmaceuticals-18-00186" ref-type="bibr">21</xref>]. Other natural matrices have shown similar effects. Indeed, our results agree with those showing that extracts of <italic toggle="yes">Albizia adianthifolia</italic> and <italic toggle="yes">Phragmanthera austroarabica</italic>, two polyphenol-rich matrices, significantly protected mice against PTZ-induced seizures, via targeting different pathways influenced by this toxin [<xref rid="B22-pharmaceuticals-18-00186" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-18-00186" ref-type="bibr">23</xref>]. Interestingly, quercetin, one of the aglycones present in WGJe, was able to hinder seizures in the same in vivo model we employed, as well as prolong the onset of seizures [<xref rid="B24-pharmaceuticals-18-00186" ref-type="bibr">24</xref>].</p><p>The anti-epileptic effects we observed in PTZ-injected ICR-CD1 mice also occurred in the AGS-susceptible DBA/2 mice. Indeed, the treatment with WGJe was able to hinder the onset of epileptic outcomes, both tonic and clonic ones, in a dose-dependent manner, as well as the typical sign of wild running. We previously demonstrated that a flavonoid-rich extract of <italic toggle="yes">Citrus sinensis</italic> juice was able to hamper seizures in the same model, as well as its main flavonoids hesperidin and narirutin [<xref rid="B25-pharmaceuticals-18-00186" ref-type="bibr">25</xref>].</p><p>We also observed that in these two models, WGJe treatment produced significant results only at the shortest timing (i.e., 30 min before PTZ injection or auditory stimulus). As documented, extensive metabolism or rapid efflux from the brain may cause a loss of the anti-epileptic potential of flavonoids, as indicated for quercetin [<xref rid="B26-pharmaceuticals-18-00186" ref-type="bibr">26</xref>].</p><p>In WAG/Rij rats, a genetic model of absence epilepsy, we did not observe a significant modulation of the SWD pattern to control rats. We speculate that this might be due to the different nature of the seizures present in this model. Absence seizures are typically treated with the employment of three AEDs, such as ethosuximide, valproic acid and lamotrigine, as first-line agents [<xref rid="B27-pharmaceuticals-18-00186" ref-type="bibr">27</xref>]. Given the mode of action of these drugs, via the blockage of T-type calcium channels by ethosuximide or voltage-gated sodium channels by lamotrigine and valproic acid, the latter being slightly active also against GABA transaminase, we suggest that molecules like polyphenols, which are thought to act mainly on the GABAergic system, may not elicit significant results in an in vivo model of absence [<xref rid="B27-pharmaceuticals-18-00186" ref-type="bibr">27</xref>]. Of note, in the same experimental model, it was shown that quercetin, at a higher dose compared to what was present in WGJe, hampered absence seizures, yet by reducing proinflammatory cytokines and nitric oxide production, suggesting that other mechanisms may be involved [<xref rid="B28-pharmaceuticals-18-00186" ref-type="bibr">28</xref>].</p><p>To prove our hypothesis that WGJe might act via targeting the GABAergic system, we employed the AGS-susceptible DBA/2 mice model co-administering WGJe with flumazenil, a GABA<sub>A</sub> antagonist. Indeed, we observed that flumazenil was able to abolish the effect of WGJe in DBA/2 mice in terms of both clonic and tonic seizures, as well as block the anxiolytic effects observed in the OFT, thus clearly suggesting the involvement of GABA<sub>A</sub> receptors. Moreover, the highest dose of WGJe (120 mg/kg) was able to revert the antagonistic effect of flumazenil, as the polyphenolic mixture present in WGJe acted competitively to restore the anti-epileptic outcome. Others have shown that polyphenols target GABA<sub>A</sub> receptors to induce their anti-epileptic effects. Indeed, resveratrol hampered kainic-acid-induced epilepsy in rats, where it reversed both chronic and silent phases of epilepsy, up-regulated the expression of the kainate glutamate receptor in the hippocampus, and down-regulated the GABA<sub>A</sub> receptor along with the increased hippocampal glutamate/GABA ratio provoked by the stressor [<xref rid="B29-pharmaceuticals-18-00186" ref-type="bibr">29</xref>].</p><p>GABA<sub>A</sub> receptors are ionotropic receptors coupled with a chlorine-dependent ion channel and are widespread in both the central and peripheral nervous systems. The natural agonist, GABA, allows the opening of the channel, thus leading to a rapid influx of chlorine and, consequently, reducing the membrane potential and inhibiting nervous transmission [<xref rid="B30-pharmaceuticals-18-00186" ref-type="bibr">30</xref>]. The GABA<sub>A</sub> subtype is the most studied due to the wide plethora of agonists and antagonists characterized by relevant clinical implications. Moreover, GABA<sub>A</sub> receptors represent one of the targets of natural compounds endowed with anti-epileptic effects [<xref rid="B31-pharmaceuticals-18-00186" ref-type="bibr">31</xref>]. Based on the effects observed after the employment of flumazenil, we wondered whether WGJe polyphenols could effectively bind to GABA<sub>A</sub> receptors. To test that, we employed molecular docking, which is acknowledged to be a promising tool for the study, design and optimization of natural products [<xref rid="B32-pharmaceuticals-18-00186" ref-type="bibr">32</xref>]. Recent crystallographic studies highlighted that within the GABA<sub>A</sub> receptor, there are two different binding domains: the ECD and the TMD [<xref rid="B15-pharmaceuticals-18-00186" ref-type="bibr">15</xref>,<xref rid="B30-pharmaceuticals-18-00186" ref-type="bibr">30</xref>]. Regarding the former, it has been described that diazepam forms crucial bonds with Phe100 via the benzyl group, with His102 via the chlorine atom and with Ser205 via the carbonyl group, which are relevant for its activity [<xref rid="B30-pharmaceuticals-18-00186" ref-type="bibr">30</xref>].</p><p>Our results showed that the most representative polyphenols of WGJe are able to efficiently interact with ECD. In particular, we observed that cis-piceid keeps the &#x003c0;-&#x003c0; interaction with Phe100, while the two quercetin glycosides interact with Tyr160, a residue less than 2.5 &#x000c5; from Phe100, thus presumably allowing the stabilization of the subunits as allowed by the first residue to maintain an enlarged pore. This is similar to Ser205, which does not represent an interaction made by the polyphenols, whereas Gln204 and Ser206, two residues linked by peptide bonds to the crucial residue, are strongly connected with both quercetin-3-glucoside and quercetin-3-glucoronide. Remarkably, none of the polyphenols we investigated interacted with Tyr142 or with Try207, two relevant residues for the antagonistic effects of flumazenil [<xref rid="B15-pharmaceuticals-18-00186" ref-type="bibr">15</xref>].</p><p>Regarding the TMD, benzodiazepines are thought to dive into the interfaces between the two &#x003b1;1 and the two &#x003b2;2 subunits, thus creating two separate yet identical binding sites [<xref rid="B15-pharmaceuticals-18-00186" ref-type="bibr">15</xref>,<xref rid="B30-pharmaceuticals-18-00186" ref-type="bibr">30</xref>]. In these cavities, diazepam binds under Asn265 of the &#x003b2; subunit and Ile228 at the short &#x003c0;-helix within the &#x003b1; subunit. Moreover, the benzyl ring of diazepam makes electrostatic contacts with Asn265, which is a key residue for pre-clinical anesthetic effects [<xref rid="B33-pharmaceuticals-18-00186" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-18-00186" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-18-00186" ref-type="bibr">35</xref>], as well as forms stacking interactions with Phe289. Among the polyphenols we investigated, cis-piceid interacted with the relevant Ile228 while quercetin-3-glucoronide interacted with Asn265, like diazepam. Quercetin-3-glucoside shared those connections, as well as &#x003c0;-&#x003c0; interaction with Phe289 and, interestingly, it formed an H-bond with Pro233, which represents a link for the phenyl ring of diazepam to interact with both &#x003b2; and &#x003b1; subunits to maintain the GABA<sub>A</sub> activated structure [<xref rid="B15-pharmaceuticals-18-00186" ref-type="bibr">15</xref>]. A novel binding site has been found for diazepam by Kim and co-workers, which lies deep between the &#x003b3; and &#x003b2; subunits at the TMD interface. We also performed our docking simulation on this site, and yet the protocol could not be validated due to a high RMSD value for the reference ligand (&#x0003e; 2 &#x000c5;), despite setting as constraints and keeping flexible the residues known to be involved in this interaction. This could be because the experimental conditions employed to retrieve the crystal structure are complex, and thus the genetic algorithm used by docking software cannot always provide consistent results. Previous reports have shown that natural compounds can interact with GABA<sub>A</sub> subunits in the benzodiazepine sites to elicit sedative or anti-epileptic effects. Along this line, the soy isoflavone daidzein dose-dependently and significantly reduced the latency whilst increasing the sleep duration of male Swiss albino mice. This effect was counteracted by flumazenil, employed to assess the involvement of GABA<sub>A</sub> receptors. Also, in this study, molecular dockings and dynamics demonstrated the binding capacity of isoflavone to interact with the benzodiazepine sites [<xref rid="B36-pharmaceuticals-18-00186" ref-type="bibr">36</xref>]. Similarly, tetrahydrolinalool, an acyclic monoterpene alcohol present in essential oils, produced anti-convulsant effects in picrotoxin-, 3-mercapto-propionic acid- and PTZ-injected mice. Moreover, the in silico studies showed that the monoterpene formed a stable complex with the GABA<sub>A</sub> receptor, similar to diazepam [<xref rid="B37-pharmaceuticals-18-00186" ref-type="bibr">37</xref>].</p><p>Apart from GABA<sub>A</sub>, the alteration of the glutamate balance is thought to be relevant in the onset of epilepsy [<xref rid="B38-pharmaceuticals-18-00186" ref-type="bibr">38</xref>], as well as other neurotransmitters. Indeed, acetylcholine has been suggested to be involved in the excitation of neurons and epilepsy [<xref rid="B39-pharmaceuticals-18-00186" ref-type="bibr">39</xref>]. Monoamines (i.e., norepinephrine, dopamine, serotonin, histamine and melatonin) are acknowledged for their role in reducing seizures and ameliorating epileptic outcomes [<xref rid="B40-pharmaceuticals-18-00186" ref-type="bibr">40</xref>]. Another significant molecule that functions as a neurotransmitter and a second messenger is nitric oxide (NO), which is synthesized by nitric oxide synthase (NOS) [<xref rid="B41-pharmaceuticals-18-00186" ref-type="bibr">41</xref>]. This enzyme may be found either in pre- or post-synaptic neurons, and it can influence behavior, learning, memory, neurotoxicity, synaptic flexibility and neuronal signaling, thus being relevant in epilepsy [<xref rid="B42-pharmaceuticals-18-00186" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00186" ref-type="bibr">43</xref>]. Therefore, there are several pathways involved in this pathology, which may be influenced by WGJe in achieving anti-epileptic outcomes along with the GABAergic one.</p></sec><sec id="sec4-pharmaceuticals-18-00186"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-18-00186"><title>4.1. Quali-Quantitative Characterization of WGJe</title><p>The WGJe used in this study was obtained from juice provided by the company &#x0201c;Bono &#x00026; Ditta&#x0201d; (Campobello di Mazara, Trapani, Italy). By means of ultra-performance liquid chromatography coupled with a triple quadrupole electrospray tandem mass spectrometry (UPLC-QqQ-MS/MS), the quali-quantitative characterization of WGJe was performed. The separation of the phenolic and polyphenolic compounds was achieved at 40 &#x000b0;C, employing a Waters Acquity HSS T3 1.8 &#x000b5;m column (Milford, MA, USA). The mobile phase A consisted of a water solution of 0.1% formic acid, while the acetonitrile solution of 0.1% formic acid was mobile phase B. Through analysis, samples were kept at 4 &#x000b0;C and a flow rate of 0.4 mL/min. Mass spectrometry detection was accomplished, as reported [<xref rid="B44-pharmaceuticals-18-00186" ref-type="bibr">44</xref>].</p></sec><sec id="sec4dot2-pharmaceuticals-18-00186"><title>4.2. Animals</title><p>Male WAG/Rij rats (6&#x02013;7 months old, 250&#x02013;300 g), DBA/2 (22&#x02013;26 days old) and ICR- CD1 mice of 6 weeks of age were purchased from Charles River Laboratories Srl (Calco, Lecco, Italy). Animals were housed in groups of 10 per cage, maintaining a controlled humidity (60 &#x000b1; 5%) and temperature (21 &#x000b1; 2 &#x000b0;C), with a light cycle of 12/12 h. Food and tap water were available ad libitum until the time of the experiments. Procedures involving animals and their care were conducted in conformity with the international and national laws and policies (EU Directive 2010/63/EU for animal experiments, ARRIVE guidelines and the Basel declaration, including the 3R concept). The experimental protocol here reported was approved by the Animal Care Committee of the University of Catanzaro (Italy) and authorized by the Italian Ministry of Research and University (MIUR; authorization n&#x000b0; 425/2017-PR). All efforts were made to minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data.</p></sec><sec id="sec4dot3-pharmaceuticals-18-00186"><title>4.3. PTZ-Induced Seizures in ICR CD-1 Mice</title><p>This experiment protocol was performed to assess the effect of several doses of WGJe (20, 40, 80, 100 and 120 mg/kg) or its vehicle (sterile saline solution 0.9% NaCl) i.p. administered in male ICR CD-1 mice 30, 60 or 120 min before the injection of PTZ (60 mg/kg, i.p.) [<xref rid="B45-pharmaceuticals-18-00186" ref-type="bibr">45</xref>]. PTZ was purchased from Sigma Aldrich, Milan, Italy. By virtue of this, ICR CD-1 mice (n = 180) were randomly divided into 6 groups (per dose and vehicle), and each of these into 3 subgroups, 1 for the different times of administration (before the injection of PTZ). Ten mice were present in each subgroup. Briefly, mice were placed in a 30 &#x000d7; 30 &#x000d7; 30 cm Plexiglas box and monitored for 30 min. During this observational time, seizures were scored as previously described [<xref rid="B46-pharmaceuticals-18-00186" ref-type="bibr">46</xref>]. Clonic spasms were considered significant if they lasted more than 5 s each. Absence of this threshold convulsion over 30 min revealed that the mouse was protected from seizures [<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>]. Times and routes of drug administration were chosen based on previously published papers or personal pilot studies [<xref rid="B25-pharmaceuticals-18-00186" ref-type="bibr">25</xref>,<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceuticals-18-00186" ref-type="bibr">48</xref>].</p></sec><sec id="sec4dot4-pharmaceuticals-18-00186"><title>4.4. Audiogenic Seizures in DBA/2 Mice</title><p>To investigate the effects of WGJe treatment on DBA/2 mice, we carried out two experimental protocols. The experiments on DBA/2 mice, weighing 8&#x02013;12 g (22&#x02013;26 days old), were performed according to the method previously described [<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>].</p><sec id="sec4dot4dot1-pharmaceuticals-18-00186"><title>4.4.1. Experimental Protocol #1</title><p>DBA/2 mice were exposed to auditory stimulation 30, 60 and 120 min following i.p. administration of WGJe (20, 40, 80, 100 and 120 mg/kg) or a vehicle [<xref rid="B25-pharmaceuticals-18-00186" ref-type="bibr">25</xref>,<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>]. To perform this, DBA/2 mice (n = 180) were randomly divided into 6 groups (n = 30 per dose and vehicle) and each of these into 3 subgroups (n = 10) for the different times of administration before auditory stimulation. Briefly, each mouse, used only once, was sited under a hemispheric Perspex dome (diameter 58 cm), and the auditory stimulation (12&#x02013;16 kHz, 109 dB) was delivered as previously described, as well as further scoring [<xref rid="B25-pharmaceuticals-18-00186" ref-type="bibr">25</xref>]. The maximum response was recorded for each mouse. Behavioral changes were monitored during the time of drug administration and auditory stimulation.</p></sec><sec id="sec4dot4dot2-pharmaceuticals-18-00186"><title>4.4.2. Experimental Protocol #2 (Co-Administration Protocol)</title><p>To investigate the contribution of the GABA<sub>A</sub> receptor to the anti-seizure effects of WGJe, flumazenil (Hoffmann-LaRoche, Basel, Switzerland), at a dose of 2.5 mg/Kg, was i.p. administered 15 min after the injection of WGJe at several doses (20, 40, 80, 100 and 120 mg/kg), whereas the auditory stimulus was delivered 30 min after WGJe injection, as previously described [<xref rid="B25-pharmaceuticals-18-00186" ref-type="bibr">25</xref>]. Times and routes of flumazenil administration were chosen based on previously published papers in which it was shown not to worsen reflex seizures when administered alone. The total number of DBA/2 mice that developed audiogenic seizures was scored at each dose used [<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>,<xref rid="B49-pharmaceuticals-18-00186" ref-type="bibr">49</xref>].</p></sec></sec><sec id="sec4dot5-pharmaceuticals-18-00186"><title>4.5. Experiments in WAG/Rij Rats</title><p>To investigate the role of WGJe in counteracting absence seizures, male WAG/Rij rats were used as a well-validated model of absence epilepsy and epileptogenesis with neuropsychiatric comorbidities. For EEG recordings, WAG/Rij rats of ~6 months of age, under anesthesia, were stereotaxically implanted with 3 cortical electrodes for EEG recordings, as previously described [<xref rid="B50-pharmaceuticals-18-00186" ref-type="bibr">50</xref>]. After surgery, all WAG/Rij rats were allowed to rest for at least 1 week of recovery. For at least 72 h before the experiments, animals were connected to the recording cables to habituate them to the recording conditions. Following this period, rats were connected to a multichannel amplifier (Pinnacle Technology&#x02019;s 8400&#x02013;9000 video/EEG system with Sirenia Software 1.7.9, Lawrence, KS, USA) by a flexible recording cable and an electric swivel, sited above the cages, allowing free movements for the animals [<xref rid="B50-pharmaceuticals-18-00186" ref-type="bibr">50</xref>]. WAG/Rij rats (n = 8 for each dose) were i.p. administered with WGJe (20, 40, 80, 100 and 120 mg/kg) or saline. The number and duration of SWDs was assessed by video-EEG recording, as described [<xref rid="B50-pharmaceuticals-18-00186" ref-type="bibr">50</xref>]. All EEG signals were amplified and conditioned, and they were digitally converted with a sampling rate of 300 Hz. The quantification of absence seizures was performed as previously described [<xref rid="B51-pharmaceuticals-18-00186" ref-type="bibr">51</xref>].</p></sec><sec id="sec4dot6-pharmaceuticals-18-00186"><title>4.6. Behavioral Test</title><p>Different groups of mice, for each dose used, were examined in the OFT, in order to study the effects of acute WGJe treatment, administered 30 min before the test, on the development of anxiety-related behavior in DBA/2 mice (n = 10 per vehicle and dose). Furthermore, other groups of mice (n = 10 per dose of WGJe and vehicle) also received flumazenil at 2.5 mg/kg i.p., in order to investigate the potential contribution of the GABA<sub>A</sub> receptor to the anxiolytic-like effect of WGJe.</p><p>This test was performed under a controlled temperature and humidity, whereas light intensity was determined by the experimental setup. Each behavioral test started at 9:00 am and finished before 11:00 am to avoid potential circadian alteration of the test results [<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>].</p><sec><title>Open-Field Test (OFT)</title><p>Anxiety-like behavior was monitored for 10 min in an open field arena, a white 70 &#x000d7; 70 cm Plexiglas apparatus with the floor divided into 9 squares. Each mouse was gently placed in the central square of the apparatus and its activity scored. Before each trial, the arena was systematically cleaned. During the test, the time spent in the center and the number of center entries were analyzed, for both treated and untreated mice, in order to test anxiety-like behavior. Lower exploratory activity in the OFT is usually taken as a measure of an increased level of anxiety and vice versa. Moreover, the total distance moved (cm), and the mean velocity (sec) during the 10 min test were also statistically analyzed, for treated and untreated mice, in order to test locomotor activity.</p></sec></sec><sec id="sec4dot7-pharmaceuticals-18-00186"><title>4.7. Statistical Analysis</title><p>All data are given as the mean &#x000b1; SEM. The statistical software used was GraphPad Prism 6.0 (La Jolla, CA, USA). Regarding DBA/2 mice, statistical comparisons among groups were carried out through Fisher&#x02019;s exact probability test (incidence of the seizure phases). The percent occurrence of audiogenic seizure phases was evaluated for each administered compound, and the dose&#x02013;response curves were close-fitted through the linear regression method, as previously described [<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>]. ED<sub>50</sub> values (&#x000b1;95% confidence limits) for each compound and each seizure phase were calculated as reported [<xref rid="B25-pharmaceuticals-18-00186" ref-type="bibr">25</xref>]. The scores of seizure severity were compared among groups by employing the Kruskall&#x02013;Wallis nonparametric analysis of variance (ANOVA), which was followed by a Mann&#x02013;Whitney U-test. Regarding WAG/Rij rats, the duration and number of SWDs were evaluated separately for every 30 min epoch [<xref rid="B25-pharmaceuticals-18-00186" ref-type="bibr">25</xref>,<xref rid="B47-pharmaceuticals-18-00186" ref-type="bibr">47</xref>]. Data was analyzed by one-way ANOVA, followed by Bonferroni&#x02019;s post hoc test. All tests were two-sided, with <italic toggle="yes">p</italic> &#x0003c; 0.05 considered significant.</p></sec><sec id="sec4dot8-pharmaceuticals-18-00186"><title>4.8. Docking Studies</title><p>The ligand structures of the chosen WGJe polyphenols were designed using the Maestro 14.0 software (Schr&#x000f6;dinger LLC; New York, NY, USA) and minimized to produce low-energy 3D structures in order to further proceed with the docking studies. We set a pH range of 7.2&#x02013;7.4 to mimic physiological conditions. The docking studies were performed by GOLD software (Hermes 2024.1.0, Cambridge Crystallographic Data Centre; Cambridge, UK). The crystal structure of the GABA<sub>A</sub> receptor in complex with diazepam was retrieved from the RCSB Protein Data Bank (entry code: 6X3X) [<xref rid="B15-pharmaceuticals-18-00186" ref-type="bibr">15</xref>]. The ligands and water molecules were removed, while hydrogens were added by Maestro 14.0 software (Schr&#x000f6;dinger LLC). Docking simulations were performed, setting the region of interest to contain the residues within 10 &#x000c5; from the position of diazepam in the X-ray structure. GoldScore and ChemPLP were employed as fitness functions. Default settings were used, and the ligands were submitted to 100 genetic algorithm runs. The results differing by less than 0.75 &#x000c5; in ligands&#x02014;all atom RMSDs were clustered together. The interactions of the best-ranked conformations with the surrounding residues were investigated by Maestro 14.0 software (Schr&#x000f6;dinger LLC). Images were acquired by PyMOL 2.6.0 software (Schr&#x000f6;dinger LLC) [<xref rid="B52-pharmaceuticals-18-00186" ref-type="bibr">52</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceuticals-18-00186"><title>5. Conclusions</title><p>Our results demonstrate that WGJe employed in this study hampered the onset of seizures in PTZ-injected ICR CD-1 mice and in AGS-sensible DBA/2 mice. The antagonistic effect of flumazenil suggests that GABA<sub>A</sub> receptors are involved in the anti-epileptic and anxiolytic effects of WGJe. Indeed, docking simulations supported the ability of the most abundant polyphenols present in WGJe to interact with the benzodiazepine sites of GABA<sub>A</sub> receptor, unravelling their putative mode of action. Given the multi-target capability of natural products and the complexity of epilepsy, other mechanisms of action may contribute to the seizure-inhibiting effects exerted by WGJe. Altogether, this extract may represent an efficient tool for epilepsy management.</p></sec></body><back><ack><title>Acknowledgments</title><p>A PON Industrial PhD fellowship from the Italian Minister of Instruction, University and Research (MIUR) to Caterina Russo (CUP: J11B21008430007) is gratefully acknowledged.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>R.C. and A.L. performed the in vivo experiments and analyzed the data; A.M. performed the in silico experiments and analyzed the data; R.C. and A.M. drafted the paper; C.R. supported the chemical characterization experiments; M.N. and G.D.S. conceived and designed the experiments, as well as revised the paper. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Animal Care Committee of the University &#x0201c;Magna Gr&#x000e6;cia&#x0201d; of Catanzaro, Italy (authorization n&#x000b0; 425/2017-PR).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed at the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00186"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zuberi</surname><given-names>S.M.</given-names></name>
<name><surname>Wirrell</surname><given-names>E.</given-names></name>
<name><surname>Yozawitz</surname><given-names>E.</given-names></name>
<name><surname>Wilmshurst</surname><given-names>J.M.</given-names></name>
<name><surname>Specchio</surname><given-names>N.</given-names></name>
<name><surname>Riney</surname><given-names>K.</given-names></name>
<name><surname>Pressler</surname><given-names>R.</given-names></name>
<name><surname>Auvin</surname><given-names>S.</given-names></name>
<name><surname>Samia</surname><given-names>P.</given-names></name>
<name><surname>Hirsch</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions</article-title><source>Epilepsia</source><year>2022</year><volume>63</volume><fpage>1349</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1111/epi.17239</pub-id><pub-id pub-id-type="pmid">35503712</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00186"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trinka</surname><given-names>E.</given-names></name>
<name><surname>Rainer</surname><given-names>L.J.</given-names></name>
<name><surname>Granbichler</surname><given-names>C.A.</given-names></name>
<name><surname>Zimmermann</surname><given-names>G.</given-names></name>
<name><surname>Leitinger</surname><given-names>M.</given-names></name>
</person-group><article-title>Mortality, and life expectancy in Epilepsy and Status epilepticus-current trends and future aspects</article-title><source>Front. Epidemiol.</source><year>2023</year><volume>3</volume><elocation-id>1081757</elocation-id><pub-id pub-id-type="doi">10.3389/fepid.2023.1081757</pub-id><pub-id pub-id-type="pmid">38455899</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00186"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hakami</surname><given-names>T.</given-names></name>
</person-group><article-title>Neuropharmacology of Antiseizure Drugs</article-title><source>Neuropsychopharmacol. Rep.</source><year>2021</year><volume>41</volume><fpage>336</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1002/npr2.12196</pub-id><pub-id pub-id-type="pmid">34296824</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00186"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elkommos</surname><given-names>S.</given-names></name>
<name><surname>Mula</surname><given-names>M.</given-names></name>
</person-group><article-title>Current and future pharmacotherapy options for drug-resistant epilepsy</article-title><source>Expert. Opin. Pharmacother.</source><year>2022</year><volume>23</volume><fpage>2023</fpage><lpage>2034</lpage><pub-id pub-id-type="doi">10.1080/14656566.2022.2128670</pub-id><pub-id pub-id-type="pmid">36154780</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00186"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wise</surname><given-names>J.</given-names></name>
</person-group><article-title>FDA approves its first cannabis based medicine</article-title><source>BMJ</source><year>2018</year><volume>361</volume><fpage>k2827</fpage><pub-id pub-id-type="doi">10.1136/bmj.k2827</pub-id><pub-id pub-id-type="pmid">29950322</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00186"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreira</surname><given-names>F.A.</given-names></name>
<name><surname>de Oliveira</surname><given-names>A.C.P.</given-names></name>
<name><surname>Santos</surname><given-names>V.R.</given-names></name>
<name><surname>Moraes</surname><given-names>M.F.D.</given-names></name>
</person-group><article-title>Cannabidiol and epilepsy</article-title><source>Int. Rev. Neurobiol.</source><year>2024</year><volume>177</volume><fpage>135</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/bs.irn.2024.03.009</pub-id><pub-id pub-id-type="pmid">39029983</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00186"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loscher</surname><given-names>W.</given-names></name>
</person-group><article-title>Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>730257</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.730257</pub-id><pub-id pub-id-type="pmid">34776956</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00186"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dhir</surname><given-names>A.</given-names></name>
</person-group><article-title>Natural polyphenols in preclinical models of epilepsy</article-title><source>Phytother. Res.</source><year>2020</year><volume>34</volume><fpage>1268</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1002/ptr.6617</pub-id><pub-id pub-id-type="pmid">32061189</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00186"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pazos-Tomas</surname><given-names>C.C.</given-names></name>
<name><surname>Cruz-Venegas</surname><given-names>A.</given-names></name>
<name><surname>Perez-Santiago</surname><given-names>A.D.</given-names></name>
<name><surname>Sanchez-Medina</surname><given-names>M.A.</given-names></name>
<name><surname>Matias-Perez</surname><given-names>D.</given-names></name>
<name><surname>Garcia-Montalvo</surname><given-names>I.A.</given-names></name>
</person-group><article-title>Vitis vinifera: An Alternative for the Prevention of Neurodegenerative Diseases</article-title><source>J. Oleo Sci.</source><year>2020</year><volume>69</volume><fpage>1147</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.5650/jos.ess20109</pub-id><pub-id pub-id-type="pmid">32908097</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00186"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andreucci</surname><given-names>M.</given-names></name>
<name><surname>Faga</surname><given-names>T.</given-names></name>
<name><surname>Pisani</surname><given-names>A.</given-names></name>
<name><surname>Sabbatini</surname><given-names>M.</given-names></name>
<name><surname>Russo</surname><given-names>D.</given-names></name>
<name><surname>Mattivi</surname><given-names>F.</given-names></name>
<name><surname>De Sarro</surname><given-names>G.</given-names></name>
<name><surname>Navarra</surname><given-names>M.</given-names></name>
<name><surname>Michael</surname><given-names>A.</given-names></name>
</person-group><article-title>Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract</article-title><source>Chem. Biol. Interact.</source><year>2015</year><volume>229</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2014.12.035</pub-id><pub-id pub-id-type="pmid">25603236</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00186"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Filocamo</surname><given-names>A.</given-names></name>
<name><surname>Bisignano</surname><given-names>C.</given-names></name>
<name><surname>Mandalari</surname><given-names>G.</given-names></name>
<name><surname>Navarra</surname><given-names>M.</given-names></name>
</person-group><article-title>In Vitro Antimicrobial Activity and Effect on Biofilm Production of a White Grape Juice (<italic toggle="yes">Vitis vinifera</italic>) Extract</article-title><source>Evid. Based Complement. Alternat Med.</source><year>2015</year><volume>2015</volume><fpage>856243</fpage><pub-id pub-id-type="doi">10.1155/2015/856243</pub-id><pub-id pub-id-type="pmid">26770255</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00186"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giacoppo</surname><given-names>S.</given-names></name>
<name><surname>Galuppo</surname><given-names>M.</given-names></name>
<name><surname>Lombardo</surname><given-names>G.E.</given-names></name>
<name><surname>Ulaszewska</surname><given-names>M.M.</given-names></name>
<name><surname>Mattivi</surname><given-names>F.</given-names></name>
<name><surname>Bramanti</surname><given-names>P.</given-names></name>
<name><surname>Mazzon</surname><given-names>E.</given-names></name>
<name><surname>Navarra</surname><given-names>M.</given-names></name>
</person-group><article-title>Neuroprotective effects of a polyphenolic white grape juice extract in a mouse model of experimental autoimmune encephalomyelitis</article-title><source>Fitoterapia</source><year>2015</year><volume>103</volume><fpage>171</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2015.04.003</pub-id><pub-id pub-id-type="pmid">25863350</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00186"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montalbano</surname><given-names>G.</given-names></name>
<name><surname>Maugeri</surname><given-names>A.</given-names></name>
<name><surname>Guerrera</surname><given-names>M.C.</given-names></name>
<name><surname>Miceli</surname><given-names>N.</given-names></name>
<name><surname>Navarra</surname><given-names>M.</given-names></name>
<name><surname>Barreca</surname><given-names>D.</given-names></name>
<name><surname>Cirmi</surname><given-names>S.</given-names></name>
<name><surname>Germana</surname><given-names>A.</given-names></name>
</person-group><article-title>A White Grape Juice Extract Reduces Fat Accumulation through the Modulation of Ghrelin and Leptin Expression in an In Vivo Model of Overfed Zebrafish</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>1119</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26041119</pub-id><pub-id pub-id-type="pmid">33672773</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00186"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prut</surname><given-names>L.</given-names></name>
<name><surname>Belzung</surname><given-names>C.</given-names></name>
</person-group><article-title>The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review</article-title><source>Eur. J. Pharmacol.</source><year>2003</year><volume>463</volume><fpage>3</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(03)01272-X</pub-id><pub-id pub-id-type="pmid">12600700</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00186"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.J.</given-names></name>
<name><surname>Gharpure</surname><given-names>A.</given-names></name>
<name><surname>Teng</surname><given-names>J.</given-names></name>
<name><surname>Zhuang</surname><given-names>Y.</given-names></name>
<name><surname>Howard</surname><given-names>R.J.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Noviello</surname><given-names>C.M.</given-names></name>
<name><surname>Walsh</surname><given-names>R.M.</given-names><suffix>Jr.</suffix></name>
<name><surname>Lindahl</surname><given-names>E.</given-names></name>
<name><surname>Hibbs</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Shared structural mechanisms of general anaesthetics and benzodiazepines</article-title><source>Nature</source><year>2020</year><volume>585</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2654-5</pub-id><pub-id pub-id-type="pmid">32879488</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00186"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharifi-Rad</surname><given-names>J.</given-names></name>
<name><surname>Quispe</surname><given-names>C.</given-names></name>
<name><surname>Herrera-Bravo</surname><given-names>J.</given-names></name>
<name><surname>Martorell</surname><given-names>M.</given-names></name>
<name><surname>Sharopov</surname><given-names>F.</given-names></name>
<name><surname>Tumer</surname><given-names>T.B.</given-names></name>
<name><surname>Kurt</surname><given-names>B.</given-names></name>
<name><surname>Lankatillake</surname><given-names>C.</given-names></name>
<name><surname>Docea</surname><given-names>A.O.</given-names></name>
<name><surname>Moreira</surname><given-names>A.C.</given-names></name>
<etal/>
</person-group><article-title>A Pharmacological Perspective on Plant-derived Bioactive Molecules for Epilepsy</article-title><source>Neurochem. Res.</source><year>2021</year><volume>46</volume><fpage>2205</fpage><lpage>2225</lpage><pub-id pub-id-type="doi">10.1007/s11064-021-03376-0</pub-id><pub-id pub-id-type="pmid">34120291</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00186"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Copmans</surname><given-names>D.</given-names></name>
<name><surname>Orellana-Paucar</surname><given-names>A.M.</given-names></name>
<name><surname>Steurs</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Ny</surname><given-names>A.</given-names></name>
<name><surname>Foubert</surname><given-names>K.</given-names></name>
<name><surname>Exarchou</surname><given-names>V.</given-names></name>
<name><surname>Siekierska</surname><given-names>A.</given-names></name>
<name><surname>Kim</surname><given-names>Y.</given-names></name>
<name><surname>De Borggraeve</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Methylated flavonoids as anti-seizure agents: Naringenin 4&#x02032;,7-dimethyl ether attenuates epileptic seizures in zebrafish and mouse models</article-title><source>Neurochem. Int.</source><year>2018</year><volume>112</volume><fpage>124</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2017.11.011</pub-id><pub-id pub-id-type="pmid">29174382</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00186"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>M.K.A.</given-names></name>
<name><surname>da Silva</surname><given-names>A.W.</given-names></name>
<name><surname>Dos Santos Moura</surname><given-names>A.L.</given-names></name>
<name><surname>Sales</surname><given-names>K.V.B.</given-names></name>
<name><surname>Marinho</surname><given-names>E.M.</given-names></name>
<name><surname>do Nascimento Martins Cardoso</surname><given-names>J.</given-names></name>
<name><surname>Marinho</surname><given-names>M.M.</given-names></name>
<name><surname>Bandeira</surname><given-names>P.N.</given-names></name>
<name><surname>Magalhaes</surname><given-names>F.E.A.</given-names></name>
<name><surname>Marinho</surname><given-names>E.S.</given-names></name>
<etal/>
</person-group><article-title>Chalcones reverse the anxiety and convulsive behavior of adult zebrafish</article-title><source>Epilepsy Behav.</source><year>2021</year><volume>117</volume><fpage>107881</fpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2021.107881</pub-id><pub-id pub-id-type="pmid">33711684</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00186"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malanik</surname><given-names>M.</given-names></name>
<name><surname>Culenova</surname><given-names>M.</given-names></name>
<name><surname>Sychrova</surname><given-names>A.</given-names></name>
<name><surname>Skiba</surname><given-names>A.</given-names></name>
<name><surname>Skalicka-Wozniak</surname><given-names>K.</given-names></name>
<name><surname>Smejkal</surname><given-names>K.</given-names></name>
</person-group><article-title>Treating Epilepsy with Natural Products: Nonsense or Possibility?</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>1061</elocation-id><pub-id pub-id-type="doi">10.3390/ph16081061</pub-id><pub-id pub-id-type="pmid">37630977</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00186"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Challal</surname><given-names>S.</given-names></name>
<name><surname>Skiba</surname><given-names>A.</given-names></name>
<name><surname>Langlois</surname><given-names>M.</given-names></name>
<name><surname>Esguerra</surname><given-names>C.V.</given-names></name>
<name><surname>Wolfender</surname><given-names>J.L.</given-names></name>
<name><surname>Crawford</surname><given-names>A.D.</given-names></name>
<name><surname>Skalicka-Wozniak</surname><given-names>K.</given-names></name>
</person-group><article-title>Natural product-derived therapies for treating drug-resistant epilepsies: From ethnopharmacology to evidence-based medicine</article-title><source>J. Ethnopharmacol.</source><year>2023</year><volume>317</volume><fpage>116740</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2023.116740</pub-id><pub-id pub-id-type="pmid">37315641</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00186"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gasior</surname><given-names>M.</given-names></name>
<name><surname>Ungard</surname><given-names>J.T.</given-names></name>
<name><surname>Beekman</surname><given-names>M.</given-names></name>
<name><surname>Carter</surname><given-names>R.B.</given-names></name>
<name><surname>Witkin</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: Comparison with diazepam and valproate</article-title><source>Neuropharmacology</source><year>2000</year><volume>39</volume><fpage>1184</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(99)00190-2</pub-id><pub-id pub-id-type="pmid">10760361</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00186"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nkwingwa</surname><given-names>B.K.</given-names></name>
<name><surname>Wado</surname><given-names>E.K.</given-names></name>
<name><surname>Foyet</surname><given-names>H.S.</given-names></name>
<name><surname>Bouvourne</surname><given-names>P.</given-names></name>
<name><surname>Jugha</surname><given-names>V.T.</given-names></name>
<name><surname>Mambou</surname><given-names>A.</given-names></name>
<name><surname>Bila</surname><given-names>R.B.</given-names></name>
<name><surname>Taiwe</surname><given-names>G.S.</given-names></name>
</person-group><article-title>Ameliorative effects of Albizia adianthifolia aqueous extract against pentylenetetrazole-induced epilepsy and associated memory loss in mice: Role of GABAergic, antioxidant defense and anti-inflammatory systems</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>165</volume><elocation-id>115093</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115093</pub-id><pub-id pub-id-type="pmid">37392651</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00186"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aldawsari</surname><given-names>H.M.</given-names></name>
<name><surname>Eid</surname><given-names>B.G.</given-names></name>
<name><surname>Neamatallah</surname><given-names>T.</given-names></name>
<name><surname>Zaitone</surname><given-names>S.A.</given-names></name>
<name><surname>Badr</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Anticonvulsant and Neuroprotective Activities of Phragmanthera austroarabica Extract in Pentylenetetrazole-Kindled Mice</article-title><source>Evid. Based Complement. Alternat Med.</source><year>2017</year><volume>2017</volume><fpage>5148219</fpage><pub-id pub-id-type="doi">10.1155/2017/5148219</pub-id><pub-id pub-id-type="pmid">28465705</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00186"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sefil</surname><given-names>F.</given-names></name>
<name><surname>Kahraman</surname><given-names>I.</given-names></name>
<name><surname>Dokuyucu</surname><given-names>R.</given-names></name>
<name><surname>Gokce</surname><given-names>H.</given-names></name>
<name><surname>Ozturk</surname><given-names>A.</given-names></name>
<name><surname>Tutuk</surname><given-names>O.</given-names></name>
<name><surname>Aydin</surname><given-names>M.</given-names></name>
<name><surname>Ozkan</surname><given-names>U.</given-names></name>
<name><surname>Pinar</surname><given-names>N.</given-names></name>
</person-group><article-title>Ameliorating effect of quercetin on acute pentylenetetrazole induced seizures in rats</article-title><source>Int. J. Clin. Exp. Med.</source><year>2014</year><volume>7</volume><fpage>2471</fpage><lpage>2477</lpage><pub-id pub-id-type="pmid">25356099</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00186"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Citraro</surname><given-names>R.</given-names></name>
<name><surname>Navarra</surname><given-names>M.</given-names></name>
<name><surname>Leo</surname><given-names>A.</given-names></name>
<name><surname>Donato Di Paola</surname><given-names>E.</given-names></name>
<name><surname>Santangelo</surname><given-names>E.</given-names></name>
<name><surname>Lippiello</surname><given-names>P.</given-names></name>
<name><surname>Aiello</surname><given-names>R.</given-names></name>
<name><surname>Russo</surname><given-names>E.</given-names></name>
<name><surname>De Sarro</surname><given-names>G.</given-names></name>
</person-group><article-title>The Anticonvulsant Activity of a Flavonoid-Rich Extract from Orange Juice Involves both NMDA and GABA-Benzodiazepine Receptor Complexes</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>1261</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21091261</pub-id><pub-id pub-id-type="pmid">27657037</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00186"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prakash</surname><given-names>C.</given-names></name>
<name><surname>Tyagi</surname><given-names>J.</given-names></name>
<name><surname>Rabidas</surname><given-names>S.S.</given-names></name>
<name><surname>Kumar</surname><given-names>V.</given-names></name>
<name><surname>Sharma</surname><given-names>D.</given-names></name>
</person-group><article-title>Therapeutic Potential of Quercetin and its Derivatives in Epilepsy: Evidence from Preclinical Studies</article-title><source>Neuromolecular Med.</source><year>2023</year><volume>25</volume><fpage>163</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s12017-022-08724-z</pub-id><pub-id pub-id-type="pmid">35951285</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00186"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kessler</surname><given-names>S.K.</given-names></name>
<name><surname>McGinnis</surname><given-names>E.</given-names></name>
</person-group><article-title>A Practical Guide to Treatment of Childhood Absence Epilepsy</article-title><source>Paediatr. Drugs</source><year>2019</year><volume>21</volume><fpage>15</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s40272-019-00325-x</pub-id><pub-id pub-id-type="pmid">30734897</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00186"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kizilaslan</surname><given-names>N.</given-names></name>
<name><surname>Aydin</surname><given-names>D.</given-names></name>
<name><surname>Sumbul</surname><given-names>O.</given-names></name>
<name><surname>Koroglu</surname><given-names>R.</given-names></name>
<name><surname>Aygun</surname><given-names>H.</given-names></name>
</person-group><article-title>The effect of quercetin on absence epilepsy in WAG/Rij rats</article-title><source>Neurol. Res.</source><year>2023</year><volume>45</volume><fpage>701</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1080/01616412.2023.2194182</pub-id><pub-id pub-id-type="pmid">36972421</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00186"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>You</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Pang</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
</person-group><article-title>Protective Effect of Resveratrol on the Brain in a Rat Model of Epilepsy</article-title><source>Neurosci. Bull.</source><year>2017</year><volume>33</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1007/s12264-017-0097-2</pub-id><pub-id pub-id-type="pmid">28161868</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00186"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masiulis</surname><given-names>S.</given-names></name>
<name><surname>Desai</surname><given-names>R.</given-names></name>
<name><surname>Uchanski</surname><given-names>T.</given-names></name>
<name><surname>Serna Martin</surname><given-names>I.</given-names></name>
<name><surname>Laverty</surname><given-names>D.</given-names></name>
<name><surname>Karia</surname><given-names>D.</given-names></name>
<name><surname>Malinauskas</surname><given-names>T.</given-names></name>
<name><surname>Zivanov</surname><given-names>J.</given-names></name>
<name><surname>Pardon</surname><given-names>E.</given-names></name>
<name><surname>Kotecha</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>GABA(A) receptor signalling mechanisms revealed by structural pharmacology</article-title><source>Nature</source><year>2019</year><volume>565</volume><fpage>454</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0832-5</pub-id><pub-id pub-id-type="pmid">30602790</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00186"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rios</surname><given-names>J.L.</given-names></name>
<name><surname>Schinella</surname><given-names>G.R.</given-names></name>
<name><surname>Moragrega</surname><given-names>I.</given-names></name>
</person-group><article-title>Phenolics as GABA(A) Receptor Ligands: An Updated Review</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>1770</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27061770</pub-id><pub-id pub-id-type="pmid">35335130</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00186"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Kirchmair</surname><given-names>J.</given-names></name>
</person-group><article-title>Cheminformatics in Natural Product-based Drug Discovery</article-title><source>Mol. Inform.</source><year>2020</year><volume>39</volume><fpage>e2000171</fpage><pub-id pub-id-type="doi">10.1002/minf.202000171</pub-id><pub-id pub-id-type="pmid">32725781</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00186"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Middendorp</surname><given-names>S.J.</given-names></name>
<name><surname>Maldifassi</surname><given-names>M.C.</given-names></name>
<name><surname>Baur</surname><given-names>R.</given-names></name>
<name><surname>Sigel</surname><given-names>E.</given-names></name>
</person-group><article-title>Positive modulation of synaptic and extrasynaptic GABAA receptors by an antagonist of the high affinity benzodiazepine binding site</article-title><source>Neuropharmacology</source><year>2015</year><volume>95</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.04.027</pub-id><pub-id pub-id-type="pmid">25963418</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00186"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeller</surname><given-names>A.</given-names></name>
<name><surname>Arras</surname><given-names>M.</given-names></name>
<name><surname>Jurd</surname><given-names>R.</given-names></name>
<name><surname>Rudolph</surname><given-names>U.</given-names></name>
</person-group><article-title>Mapping the contribution of beta3-containing GABAA receptors to volatile and intravenous general anesthetic actions</article-title><source>BMC Pharmacol.</source><year>2007</year><volume>7</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2210-7-2</pub-id><pub-id pub-id-type="pmid">17319964</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00186"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeller</surname><given-names>A.</given-names></name>
<name><surname>Arras</surname><given-names>M.</given-names></name>
<name><surname>Jurd</surname><given-names>R.</given-names></name>
<name><surname>Rudolph</surname><given-names>U.</given-names></name>
</person-group><article-title>Identification of a molecular target mediating the general anesthetic actions of pentobarbital</article-title><source>Mol. Pharmacol.</source><year>2007</year><volume>71</volume><fpage>852</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1124/mol.106.030049</pub-id><pub-id pub-id-type="pmid">17164405</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00186"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Islam</surname><given-names>M.T.</given-names></name>
<name><surname>Bhuia</surname><given-names>M.S.</given-names></name>
<name><surname>Sheikh</surname><given-names>S.</given-names></name>
<name><surname>Hasan</surname><given-names>R.</given-names></name>
<name><surname>Bappi</surname><given-names>M.H.</given-names></name>
<name><surname>Chowdhury</surname><given-names>R.</given-names></name>
<name><surname>Ansari</surname><given-names>S.A.</given-names></name>
<name><surname>Islam</surname><given-names>M.A.</given-names></name>
<name><surname>Saifuzzaman</surname><given-names>M.</given-names></name>
</person-group><article-title>Sedative Effects of Daidzin, Possibly Through the GABA(A) Receptor Interaction Pathway: In Vivo Approach with Molecular Dynamic Simulations</article-title><source>J. Mol. Neurosci.</source><year>2024</year><volume>74</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1007/s12031-024-02261-z</pub-id><pub-id pub-id-type="pmid">39230641</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00186"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fonseca</surname><given-names>D.V.</given-names></name>
<name><surname>da Silva</surname><given-names>P.R.</given-names></name>
<name><surname>Pires</surname><given-names>H.F.O.</given-names></name>
<name><surname>Rocha</surname><given-names>J.S.</given-names></name>
<name><surname>de Oliveira</surname><given-names>L.E.G.</given-names></name>
<name><surname>Reis</surname><given-names>F.M.S.</given-names></name>
<name><surname>Cavalho</surname><given-names>E.B.M.</given-names></name>
<name><surname>Pazos</surname><given-names>N.D.N.</given-names></name>
<name><surname>de Sousa</surname><given-names>N.F.</given-names></name>
<name><surname>Guedes</surname><given-names>E.C.</given-names></name>
<etal/>
</person-group><article-title>Anticonvulsant activity of Tetrahydrolinalool: Behavioral, electrophysiological, and molecular docking approaches</article-title><source>ChemMedChem</source><year>2024</year><volume>19</volume><fpage>e202400135</fpage><pub-id pub-id-type="doi">10.1002/cmdc.202400135</pub-id><pub-id pub-id-type="pmid">38687623</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00186"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akyuz</surname><given-names>E.</given-names></name>
<name><surname>Polat</surname><given-names>A.K.</given-names></name>
<name><surname>Eroglu</surname><given-names>E.</given-names></name>
<name><surname>Kullu</surname><given-names>I.</given-names></name>
<name><surname>Angelopoulou</surname><given-names>E.</given-names></name>
<name><surname>Paudel</surname><given-names>Y.N.</given-names></name>
</person-group><article-title>Revisiting the role of neurotransmitters in epilepsy: An updated review</article-title><source>Life Sci.</source><year>2021</year><volume>265</volume><fpage>118826</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118826</pub-id><pub-id pub-id-type="pmid">33259863</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00186"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Tan</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
</person-group><article-title>Cholinergic Signaling, Neural Excitability, and Epilepsy</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>2258</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26082258</pub-id><pub-id pub-id-type="pmid">33924731</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00186"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Svob Strac</surname><given-names>D.</given-names></name>
<name><surname>Pivac</surname><given-names>N.</given-names></name>
<name><surname>Smolders</surname><given-names>I.J.</given-names></name>
<name><surname>Fogel</surname><given-names>W.A.</given-names></name>
<name><surname>De Deurwaerdere</surname><given-names>P.</given-names></name>
<name><surname>Di Giovanni</surname><given-names>G.</given-names></name>
</person-group><article-title>Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs</article-title><source>Front. Neurosci.</source><year>2016</year><volume>10</volume><elocation-id>492</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2016.00492</pub-id><pub-id pub-id-type="pmid">27891070</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00186"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>E.</given-names></name>
<name><surname>Berka</surname><given-names>V.</given-names></name>
<name><surname>Tsai</surname><given-names>A.L.</given-names></name>
<name><surname>Murad</surname><given-names>F.</given-names></name>
</person-group><article-title>Soluble guanylyl cyclase: The nitric oxide receptor</article-title><source>Methods Enzymol.</source><year>2005</year><volume>396</volume><fpage>478</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(05)96040-0</pub-id><pub-id pub-id-type="pmid">16291255</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00186"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banach</surname><given-names>M.</given-names></name>
<name><surname>Piskorska</surname><given-names>B.</given-names></name>
<name><surname>Czuczwar</surname><given-names>S.J.</given-names></name>
<name><surname>Borowicz</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Nitric oxide, epileptic seizures, and action of antiepileptic drugs</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2011</year><volume>10</volume><fpage>808</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.2174/187152711798072347</pub-id><pub-id pub-id-type="pmid">21999730</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00186"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>M.</given-names></name>
<name><surname>Miyai</surname><given-names>A.</given-names></name>
<name><surname>Danjo</surname><given-names>S.</given-names></name>
<name><surname>Nakamura</surname><given-names>Y.</given-names></name>
<name><surname>Itoh</surname><given-names>K.</given-names></name>
</person-group><article-title>The threshold of pentylenetetrazole-induced convulsive seizures, but not that of nonconvulsive seizures, is controlled by the nitric oxide levels in murine brains</article-title><source>Exp. Neurol.</source><year>2013</year><volume>247</volume><fpage>645</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2013.02.019</pub-id><pub-id pub-id-type="pmid">23499834</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00186"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vrhovsek</surname><given-names>U.</given-names></name>
<name><surname>Masuero</surname><given-names>D.</given-names></name>
<name><surname>Gasperotti</surname><given-names>M.</given-names></name>
<name><surname>Franceschi</surname><given-names>P.</given-names></name>
<name><surname>Caputi</surname><given-names>L.</given-names></name>
<name><surname>Viola</surname><given-names>R.</given-names></name>
<name><surname>Mattivi</surname><given-names>F.</given-names></name>
</person-group><article-title>A Versatile Targeted Metabolomics Method for the Rapid Quantification of Multiple Classes of Phenolics in Fruits and Beverages</article-title><source>J. Agric. Food Chem.</source><year>2012</year><volume>60</volume><fpage>8831</fpage><lpage>8840</lpage><pub-id pub-id-type="doi">10.1021/jf2051569</pub-id><pub-id pub-id-type="pmid">22468648</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00186"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Funck</surname><given-names>V.R.</given-names></name>
<name><surname>de Oliveira</surname><given-names>C.V.</given-names></name>
<name><surname>Pereira</surname><given-names>L.M.</given-names></name>
<name><surname>Rambo</surname><given-names>L.M.</given-names></name>
<name><surname>Ribeiro</surname><given-names>L.R.</given-names></name>
<name><surname>Royes</surname><given-names>L.F.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.</given-names></name>
<name><surname>Guerra</surname><given-names>G.P.</given-names></name>
<name><surname>Furian</surname><given-names>A.F.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>Differential effects of atorvastatin treatment and withdrawal on pentylenetetrazol-induced seizures</article-title><source>Epilepsia</source><year>2011</year><volume>52</volume><fpage>2094</fpage><lpage>2104</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03261.x</pub-id><pub-id pub-id-type="pmid">21906051</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00186"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Vel&#x000ed;&#x00161;kov&#x000e1;</surname><given-names>J.</given-names></name>
<name><surname>Vel&#x000ed;&#x00161;ek</surname><given-names>L.</given-names></name>
</person-group><article-title>Behavioral Characterization and Scoring of Seizures in Rodents</article-title><source>Models of Seizures and Epilepsy</source><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B47-pharmaceuticals-18-00186"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Citraro</surname><given-names>R.</given-names></name>
<name><surname>Russo</surname><given-names>E.</given-names></name>
<name><surname>Leo</surname><given-names>A.</given-names></name>
<name><surname>Russo</surname><given-names>R.</given-names></name>
<name><surname>Avagliano</surname><given-names>C.</given-names></name>
<name><surname>Navarra</surname><given-names>M.</given-names></name>
<name><surname>Calignano</surname><given-names>A.</given-names></name>
<name><surname>De Sarro</surname><given-names>G.</given-names></name>
</person-group><article-title>Pharmacokinetic-pharmacodynamic influence of N-palmitoylethanolamine, arachidonyl-2&#x02032;-chloroethylamide and WIN 55,212-2 on the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice</article-title><source>Eur. J. Pharmacol.</source><year>2016</year><volume>791</volume><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2016.09.029</pub-id><pub-id pub-id-type="pmid">27663280</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00186"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andres-Mach</surname><given-names>M.</given-names></name>
<name><surname>Zolkowska</surname><given-names>D.</given-names></name>
<name><surname>Barcicka-Klosowska</surname><given-names>B.</given-names></name>
<name><surname>Haratym-Maj</surname><given-names>A.</given-names></name>
<name><surname>Florek-Luszczki</surname><given-names>M.</given-names></name>
<name><surname>Luszczki</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Effect of ACEA--a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2012</year><volume>39</volume><fpage>301</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.07.001</pub-id><pub-id pub-id-type="pmid">22789660</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00186"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Sarro</surname><given-names>G.</given-names></name>
<name><surname>Carotti</surname><given-names>A.</given-names></name>
<name><surname>Campagna</surname><given-names>F.</given-names></name>
<name><surname>McKernan</surname><given-names>R.</given-names></name>
<name><surname>Rizzo</surname><given-names>M.</given-names></name>
<name><surname>Falconi</surname><given-names>U.</given-names></name>
<name><surname>Palluotto</surname><given-names>F.</given-names></name>
<name><surname>Giusti</surname><given-names>P.</given-names></name>
<name><surname>Rettore</surname><given-names>C.</given-names></name>
<name><surname>De Sarro</surname><given-names>A.</given-names></name>
</person-group><article-title>Benzodiazepine receptor affinities, behavioral, and anticonvulsant activity of 2-aryl-2,5-dihydropyridazino[4,3-b]indol- 3(3H)-ones in mice</article-title><source>Pharmacol. Biochem. Behav.</source><year>2000</year><volume>65</volume><fpage>475</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(99)00230-0</pub-id><pub-id pub-id-type="pmid">10683488</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00186"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leo</surname><given-names>A.</given-names></name>
<name><surname>Citraro</surname><given-names>R.</given-names></name>
<name><surname>Amodio</surname><given-names>N.</given-names></name>
<name><surname>De Sarro</surname><given-names>C.</given-names></name>
<name><surname>Gallo Cantafio</surname><given-names>M.E.</given-names></name>
<name><surname>Constanti</surname><given-names>A.</given-names></name>
<name><surname>De Sarro</surname><given-names>G.</given-names></name>
<name><surname>Russo</surname><given-names>E.</given-names></name>
</person-group><article-title>Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model</article-title><source>Neurotherapeutics</source><year>2017</year><volume>14</volume><fpage>1134</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1007/s13311-017-0550-y</pub-id><pub-id pub-id-type="pmid">28653281</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00186"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Citraro</surname><given-names>R.</given-names></name>
<name><surname>Leo</surname><given-names>A.</given-names></name>
<name><surname>Franco</surname><given-names>V.</given-names></name>
<name><surname>Marchiselli</surname><given-names>R.</given-names></name>
<name><surname>Perucca</surname><given-names>E.</given-names></name>
<name><surname>De Sarro</surname><given-names>G.</given-names></name>
<name><surname>Russo</surname><given-names>E.</given-names></name>
</person-group><article-title>Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior</article-title><source>Epilepsia</source><year>2017</year><volume>58</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1111/epi.13629</pub-id><pub-id pub-id-type="pmid">27988935</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00186"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russo</surname><given-names>C.</given-names></name>
<name><surname>Maugeri</surname><given-names>A.</given-names></name>
<name><surname>De Luca</surname><given-names>L.</given-names></name>
<name><surname>Gitto</surname><given-names>R.</given-names></name>
<name><surname>Lombardo</surname><given-names>G.E.</given-names></name>
<name><surname>Musumeci</surname><given-names>L.</given-names></name>
<name><surname>De Sarro</surname><given-names>G.</given-names></name>
<name><surname>Cirmi</surname><given-names>S.</given-names></name>
<name><surname>Navarra</surname><given-names>M.</given-names></name>
</person-group><article-title>The SIRT2 Pathway Is Involved in the Antiproliferative Effect of Flavanones in Human Leukemia Monocytic THP-1 Cells</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>2383</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10102383</pub-id><pub-id pub-id-type="pmid">36289647</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00186-f001"><label>Figure 1</label><caption><p>Dose&#x02013;response curve for the anticonvulsant effect of WGJe (20&#x02013;120 mg/kg; i.p.) in ICR-CD1 mice intraperitoneally treated with PTZ (60 mg/kg). Abscissa shows the drug doses, ordinate shows the % of tonic seizures induced by PTZ.</p></caption><graphic xlink:href="pharmaceuticals-18-00186-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00186-f002"><label>Figure 2</label><caption><p>Dose&#x02013;response curves for the anticonvulsant effect of WGJe (20&#x02013;120 mg/kg; i.p.) in DBA/2 mice alone (blue line) and in combination with flumazenil (2.5 mg/kg; i.p.; red line). Abscissa shows the drug doses. (<bold>A</bold>) Ordinate shows the % of clonic seizures induced by audiogenic stimuli. (<bold>B</bold>) Ordinate shows the % of tonic seizures induced by audiogenic stimuli.</p></caption><graphic xlink:href="pharmaceuticals-18-00186-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00186-f003"><label>Figure 3</label><caption><p>Open-field test results for anxiety measures. (<bold>A</bold>) Blue histograms represent the time spent in central square(s). (<bold>B</bold>) Green histograms represent the number of entries in the center. Dashed histograms represent co-treatment of WGJe and flumazenil. Values are expressed as means &#x000b1; S.E.M. Data marked with * are significantly different (<italic toggle="yes">p</italic> &#x0003c; 0.01) from DBA/2-vehicle group, whereas data marked with # are significantly different (<italic toggle="yes">p</italic> &#x0003c; 0.01) from respective DBA/2 WGJe-treated mice.</p></caption><graphic xlink:href="pharmaceuticals-18-00186-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00186-f004"><label>Figure 4</label><caption><p>Crystallized structure of the GABA<sub>A</sub> receptor bound with the endogenous ligand &#x003b3;-aminobutyric acid (in blue), the agonist diazepam (in orange) and the antagonist flumazenil (in yellow; PDB: 6X3X and 6X3U superimposed).</p></caption><graphic xlink:href="pharmaceuticals-18-00186-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00186-f005"><label>Figure 5</label><caption><p>Binding modes of the highest-ranking polyphenols of WGJe and their interactions at the ECD site. (<bold>A</bold>) Best docked positions of quercetin-3-glucoside (in magenta), quercetin-3-glucoronide (in yellow) and cis-piceid (in cyan) compared to the crystallized ligand (diazepam, in orange) at the ECD site. (<bold>B</bold>&#x02013;<bold>D</bold>) Maps of interactions between docked cis-piceid (<bold>B</bold>), quercetin-3-glucoronide (<bold>C</bold>) and quercetin-3-glucoside (<bold>D</bold>) at the ECD binding site. Magenta arrows represent hydrogen bonds, while green lines represent &#x003c0;-&#x003c0; stacking.</p></caption><graphic xlink:href="pharmaceuticals-18-00186-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00186-f006"><label>Figure 6</label><caption><p>Binding modes of the highest-ranking polyphenols of WGJe and their interactions at the TMD site. (<bold>A</bold>) Best docked positions of quercetin-3-glucoside (in magenta), quercetin-3-glucoronide (in yellow) and cis-piceid (in cyan) compared to the crystallized ligand (diazepam, in orange) at the TMD site. (<bold>B</bold>&#x02013;<bold>D</bold>) Maps of interactions between docked cis-piceid (<bold>B</bold>), quercetin-3-glucoronide (<bold>C</bold>) and quercetin-3-glucoside (<bold>D</bold>) at the TMD binding site. Magenta arrows represent hydrogen bonds, while amber ones stand for halogen bonds. The green lines represent &#x003c0;-&#x003c0; stacking.</p></caption><graphic xlink:href="pharmaceuticals-18-00186-g006" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00186-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00186-t001_Table 1</object-id><label>Table 1</label><caption><p>Quali-quantitative composition of WGJe performed by UPLC/QqQ&#x02013;MS/MS analysis. Results are expressed as mg/kg of dry extract.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compounds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Concentration<break/>(mg/kg)</th></tr></thead><tbody><tr><td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Flavonols</td><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin-3-glucuronide</td><td align="center" valign="middle" rowspan="1" colspan="1">15,531.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin-3-glucoside</td><td align="center" valign="middle" rowspan="1" colspan="1">6470.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin-3,4-rutinoside</td><td align="center" valign="middle" rowspan="1" colspan="1">1266.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kaempferol-3-glucuronide</td><td align="center" valign="middle" rowspan="1" colspan="1">828.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kaempferol-3-glucoside</td><td align="center" valign="middle" rowspan="1" colspan="1">409.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Isorhamnetin-3-glucoside</td><td align="center" valign="middle" rowspan="1" colspan="1">359.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin-3-glucoside-arabinoside</td><td align="center" valign="middle" rowspan="1" colspan="1">115.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rutin</td><td align="center" valign="middle" rowspan="1" colspan="1">34.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" rowspan="1" colspan="1">27.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kaempferol-3-rutinoside</td><td align="center" valign="middle" rowspan="1" colspan="1">4.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin-3-glucoside acetyl</td><td align="center" valign="middle" rowspan="1" colspan="1">4.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isorhamnetin-3-rutinoside</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Flavanols</td><td align="center" valign="middle" rowspan="1" colspan="1">Procyanidin B1</td><td align="center" valign="middle" rowspan="1" colspan="1">7326.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Catechin</td><td align="center" valign="middle" rowspan="1" colspan="1">3355.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Procyanidin B3</td><td align="center" valign="middle" rowspan="1" colspan="1">2086.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epicatechin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">379.1</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Hydroxycinnamates</td><td align="center" valign="middle" rowspan="1" colspan="1">trans-Coutaric acid</td><td align="center" valign="middle" rowspan="1" colspan="1">2740.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caffeic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">371.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chlorogenic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">33.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">p-Coumaric acid</td><td align="center" valign="middle" rowspan="1" colspan="1">23.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferulic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.1</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Resveratrols</td><td align="center" valign="middle" rowspan="1" colspan="1">cis-Piceid</td><td align="center" valign="middle" rowspan="1" colspan="1">2295.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">trans-Piceid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.7</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Phenolic acids</td><td align="center" valign="middle" rowspan="1" colspan="1">Ellagic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">867.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">p-hydroxybenzoic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">85.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vanillic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">64.3</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">2,6-diOH-benzoic acid</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">5.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methyl gallate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dihydroflavonols</td><td align="center" valign="middle" rowspan="1" colspan="1">Taxifolin</td><td align="center" valign="middle" rowspan="1" colspan="1">491.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dihydrokaempferol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.6</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dihydrochalcones</td><td align="center" valign="middle" rowspan="1" colspan="1">Phlorizin</td><td align="center" valign="middle" rowspan="1" colspan="1">40.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trilobatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flavanones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hesperidin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.1</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Flavones</td><td align="center" valign="middle" rowspan="1" colspan="1">Luteolin-7-O-glucoside</td><td align="center" valign="middle" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Luteolin</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sinensetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydroquinones</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arbutin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">295.2</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00186-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00186-t002_Table 2</object-id><label>Table 2</label><caption><p>ED<sub>50</sub> values of PTZ-injected ICR-CD1 mice treated with WGJe, and ED<sub>50</sub> values of audiogenic seizures in DBA/2 mice treated with WGJe alone or co-administered with flumazenil (2.5 mg/kg), after 30 min from drug administration. All data reported are expressed as mg/kg and were extrapolated following the Litchfield and Wilcoxon method (1949). Values in parentheses are 95% of the confidence limit. * <italic toggle="yes">p</italic> &#x0003c; 0.01, statistically significant differences from the vehicle-drug control group. <bold><sup>#</sup></bold>&#x000a0;<italic toggle="yes">p</italic> &#x0003c; 0.01, statistically significant differences from the WGJe-treated group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Treatment</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dose Range<break/>(mg/kg)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Mice Model</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Seizure Phase</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wild Running</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clonus</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tonus</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">WGJe</td><td align="center" valign="middle" rowspan="1" colspan="1">20&#x02013;120</td><td align="center" valign="middle" rowspan="1" colspan="1">PTZ treated ICR-CD1 mice</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" rowspan="1" colspan="1">57.76 (45.48&#x02013;73.36) *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">WGJe</td><td align="center" valign="middle" rowspan="1" colspan="1">20&#x02013;120</td><td align="center" valign="middle" rowspan="1" colspan="1">DBA/2 mice</td><td align="center" valign="middle" rowspan="1" colspan="1">89.28 (62.31&#x02013;127.91) *</td><td align="center" valign="middle" rowspan="1" colspan="1">60.68 (45.76&#x02013;80.47) *</td><td align="center" valign="middle" rowspan="1" colspan="1">47.83 (33.17&#x02013;68.96) *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WGJe + Flumazenil (2.5 mg/kg)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20&#x02013;120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DBA/2 mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.95 (73.65&#x02013;132.93) <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73.94 (55.05&#x02013;99.30) <sup>#</sup></td></tr></tbody></table><table-wrap-foot><fn><p>NE: not effective.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00186-t003"><object-id pub-id-type="pii">pharmaceuticals-18-00186-t003_Table 3</object-id><label>Table 3</label><caption><p>WGJe polyphenols ranked by their docking score. The table shows the 2D structure of each polyphenol, as well as the corresponding numerical output from the GoldScore and ChemPLP algorithms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Compound </th><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Structure </th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Docking Score</th></tr><tr><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">ECD</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">TMD</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GoldScore</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChemPLP</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GoldScore</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChemPLP</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Catechin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00186-i001.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">64.67</td><td align="center" valign="middle" rowspan="1" colspan="1">75.51</td><td align="center" valign="middle" rowspan="1" colspan="1">56.69</td><td align="center" valign="middle" rowspan="1" colspan="1">66.14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cis-piceid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00186-i002.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">72.03</td><td align="center" valign="middle" rowspan="1" colspan="1">80.50</td><td align="center" valign="middle" rowspan="1" colspan="1">61.13</td><td align="center" valign="middle" rowspan="1" colspan="1">72.11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coutaric acid</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00186-i003.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">64.04</td><td align="center" valign="middle" rowspan="1" colspan="1">75.40</td><td align="center" valign="middle" rowspan="1" colspan="1">51.55</td><td align="center" valign="middle" rowspan="1" colspan="1">62.14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epicatechin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00186-i004.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">62.92</td><td align="center" valign="middle" rowspan="1" colspan="1">78.21</td><td align="center" valign="middle" rowspan="1" colspan="1">56.11 </td><td align="center" valign="middle" rowspan="1" colspan="1">66.75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00186-i005.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">66.11</td><td align="center" valign="middle" rowspan="1" colspan="1">75.86</td><td align="center" valign="middle" rowspan="1" colspan="1">53.56 </td><td align="center" valign="middle" rowspan="1" colspan="1">60.24</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin-3-glucoronide</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00186-i006.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">75.57</td><td align="center" valign="middle" rowspan="1" colspan="1">109.34</td><td align="center" valign="middle" rowspan="1" colspan="1">72.72 </td><td align="center" valign="middle" rowspan="1" colspan="1">68.06</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin-3-glucoside</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00186-i007.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76.39</td></tr></tbody></table></table-wrap></floats-group></article>